Grupo Casa Saba Announces 3Q09 Earni...(ed for 3.84% (versus3.83% during the thi...),Health

Date:10/28/2009

ed for 3.84% (versus 3.83% during the third quarter of 2008). Health, Beauty, Consumer Goods, General Merchandise and Other represented 8.49% (compared to 9.19% in the third quarter of 2008) and Publications made up the remaining 2.76% (versus 3.09% during the third quarter of 2008).

GROSS INCOME

During the third quarter of the year, Grupo Casa Saba's gross income increased 2.43% versus the same period of the previous year to reach $762.04 million. This growth was primarily driven by our Private Pharma division.

The company's gross margin was 10.87%, 26 basis points lower than the 11.13% margin posted during 3Q08. The margin was affected by an increase in the cost of sales resulting from less favorable commercial conditions with the main Brazilian wholesalers.

OPERATING EXPENSES

GCS's operating expenses reached $551.63 million in 3Q09, an increase of 6.52% compared to the third quarter of 2008. The increase in expenses continues to be related to our Brazilian operations.

Operating expenses represented 7.87% of our total sales in 3Q09 compared to 7.75% during the same period of the previous year.

OPERATING INCOME

Quarterly operating income was $210.41 million, 6.93% lower than the $226.07 reported in 3Q08. This decline was due to the fact that the growth in sales was not sufficient to offset the increase in operating expenses.

The operating margin was 3.00%, 38 basis points lower than the 3.38% margin registered in the third quarter of 2008.

OPERATING INCOME PLUS DEPRECIATION AND AMORTIZATION

Operating income plus depreciation and amortization for 3Q09 was $235.41 million, a decrease of 5.72% compared to the third quarter of 2008. Depreciation and amortization for the period was $25.00 million, 5.90% higher than in the third quarter of 2008.

CASH AND CASH EQUIVALENTS

'/>"/>

SOURCE Grupo Casa Saba Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Rochester Medical Announces Fourth Quarter 2009 Earnings Conference Call Thursday, November 5th 2009
2. BioMarin Announces Third Quarter 2009 Financial Results
3. Rigel Announces Presentations at Two Investor Conferences
4. Onyx Pharmaceuticals Announces Third Quarter 2009 Financial Results Teleconference and Webcast
5. STAAR Surgical Announces Third Quarter 2009 Earnings Release Date and Conference Call
6. CardioGenics Holdings Inc. Announces Letter to Shareholders
7. Heska Announces Q309 Results
8. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
9. Inverness Medical Innovations Announces Third Quarter 2009 Results
10. Logical Therapeutics Announces Positive Results of LT-NS001 vs. Naproxen Clinical Study
11. Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment for Primary Biliary Cirrhosis